Charles River Laboratories Pre-Tax Profit Margin 2010-2024 | CRL
Current and historical pre-tax profit margin for Charles River Laboratories (CRL) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Charles River Laboratories pre-tax profit margin for the three months ending December 31, 2024 was .
| Charles River Laboratories Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-12-31 |
$4.05B |
$0.09B |
2.30% |
| 2024-09-30 |
$4.06B |
$0.52B |
12.78% |
| 2024-06-30 |
$4.08B |
$0.54B |
13.27% |
| 2024-03-31 |
$4.11B |
$0.55B |
13.38% |
| 2023-12-31 |
$4.13B |
$0.58B |
14.10% |
| 2023-09-30 |
$4.22B |
$0.62B |
14.66% |
| 2023-06-30 |
$4.18B |
$0.63B |
15.03% |
| 2023-03-31 |
$4.09B |
$0.64B |
15.72% |
| 2022-12-31 |
$3.98B |
$0.62B |
15.67% |
| 2022-09-30 |
$3.78B |
$0.54B |
14.33% |
| 2022-06-30 |
$3.69B |
$0.54B |
14.70% |
| 2022-03-31 |
$3.63B |
$0.53B |
14.46% |
| 2021-12-31 |
$3.54B |
$0.48B |
13.56% |
| 2021-09-30 |
$3.43B |
$0.49B |
14.24% |
| 2021-06-30 |
$3.27B |
$0.50B |
15.27% |
| 2021-03-31 |
$3.04B |
$0.46B |
15.02% |
| 2020-12-31 |
$2.92B |
$0.45B |
15.25% |
| 2020-09-30 |
$2.82B |
$0.38B |
13.46% |
| 2020-06-30 |
$2.75B |
$0.32B |
11.57% |
| 2020-03-31 |
$2.72B |
$0.29B |
10.76% |
| 2019-12-31 |
$2.62B |
$0.30B |
11.59% |
| 2019-09-30 |
$2.53B |
$0.27B |
10.78% |
| 2019-06-30 |
$2.45B |
$0.27B |
11.14% |
| 2019-03-31 |
$2.38B |
$0.28B |
11.95% |
| 2018-12-31 |
$2.27B |
$0.28B |
12.40% |
| 2018-09-30 |
$2.14B |
$0.28B |
12.84% |
| 2018-06-30 |
$2.02B |
$0.28B |
13.61% |
| 2018-03-31 |
$1.91B |
$0.28B |
14.80% |
| 2017-12-31 |
$1.86B |
$0.30B |
15.99% |
| 2017-09-30 |
$1.85B |
$0.29B |
15.82% |
| 2017-06-30 |
$1.81B |
$0.27B |
15.04% |
| 2017-03-31 |
$1.77B |
$0.25B |
14.04% |
| 2016-12-31 |
$1.68B |
$0.22B |
13.26% |
| 2016-09-30 |
$1.57B |
$0.21B |
13.32% |
| 2016-06-30 |
$1.49B |
$0.21B |
14.01% |
| 2016-03-31 |
$1.40B |
$0.22B |
15.38% |
| 2015-12-31 |
$1.36B |
$0.20B |
14.31% |
| 2015-09-30 |
$1.34B |
$0.19B |
13.82% |
| 2015-06-30 |
$1.32B |
$0.18B |
13.35% |
| 2015-03-31 |
$1.32B |
$0.17B |
12.66% |
| 2014-12-31 |
$1.30B |
$0.18B |
13.71% |
| 2014-09-30 |
$1.26B |
$0.16B |
12.81% |
| 2014-06-30 |
$1.22B |
$0.16B |
13.10% |
| 2014-03-31 |
$1.17B |
$0.15B |
12.45% |
| 2013-12-31 |
$1.17B |
$0.14B |
11.93% |
| 2013-09-30 |
$1.16B |
$0.14B |
12.28% |
| 2013-06-30 |
$1.14B |
$0.13B |
11.11% |
| 2013-03-31 |
$1.14B |
$0.13B |
11.45% |
| 2012-12-31 |
$1.13B |
$0.13B |
11.42% |
| 2012-09-30 |
$1.14B |
$0.14B |
11.92% |
| 2012-06-30 |
$1.14B |
$0.13B |
11.67% |
| 2012-03-31 |
$1.14B |
$0.14B |
11.90% |
| 2011-12-31 |
$1.14B |
$0.13B |
11.72% |
| 2011-09-30 |
$1.13B |
$-0.27B |
-23.99% |
| 2011-06-30 |
$1.13B |
$-0.31B |
-27.06% |
| 2011-03-31 |
$1.13B |
$-0.33B |
-28.90% |
| 2010-12-31 |
$1.13B |
$-0.34B |
-29.54% |
| 2010-09-30 |
$1.12B |
$0.07B |
6.00% |
| 2010-06-30 |
$1.14B |
$0.12B |
10.07% |
| 2010-03-31 |
$1.16B |
$0.14B |
12.06% |
| 2009-12-31 |
$1.17B |
$0.15B |
12.89% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$8.719B |
$4.050B |
|
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
|
